25039-77-4

Basic information

• Product Name: 5-Thiazolecarboxylicacid,2-amino-4-(hydroxymethyl)-,ethylester(7CI,8CI,9CI)
• Synonyms: 5-Thiazolecarboxylicacid,2-amino-4-(hydroxymethyl)-,ethylester(7CI,8CI,9CI);ETHYL 2-AMINO-4-(HYDROXYMETHYL)THIAZOLE-5-CARBOXYLATE
• CAS NO: 25039-77-4
• Molecular Formula: C7H10N2O3S
• Molecular Weight: 202.23
• Product Categories: AMINOACID
• Mol File: 25039-77-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 183-187 °C(Solv: ethanol (64-17-5))
• Boiling Point: 425.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.417±0.06 g/cm3(Predicted)
• PKA: 12.60±0.10(Predicted)
• CAS DataBase Reference: 5-Thiazolecarboxylicacid,2-amino-4-(hydroxymethyl)-,ethylester(7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Thiazolecarboxylicacid,2-amino-4-(hydroxymethyl)-,ethylester(7CI,8CI,9CI)(25039-77-4)
• EPA Substance Registry System: 5-Thiazolecarboxylicacid,2-amino-4-(hydroxymethyl)-,ethylester(7CI,8CI,9CI)(25039-77-4)

Safety Data

• Hazardous Substances Data: 25039-77-4(Hazardous Substances Data)

Upstream product

• 5445-93-2 2-amino-4,5-bis(ethoxycarbonyl)thiazole 
• 4971-56-6 tetrahydrofuran-2,4-dione 
• 64-17-5 ethanol 
• 17356-08-0 thiourea 
• 1093115-36-6 ethyl 2-amino-4-[(benzyloxy)methyl]-1,3-thiazole-5-carboxylate 
• 4971-55-5 3-chloro-(3H,5H)-furan-2,4-dione 
• 90980-12-4 2-(4-hydroxy-2-oxo-2,5-dihydro-furan-3-yl)-isothiourea; hydrobromide 
• 67354-34-1 ethyl 4-benzyloxyacetoacetate 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Downstream Products

• 672926-42-0 ethyl 2-amino-4-cyano-1,3-thiazole-5-carboxylate 
• 907545-80-6 2-chloro-5-(ethoxy carbonyl)-1,3-thiazole-4-carboxylic acid 

Relevant articles and documents

N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidin-2-one compounds (also referred to herein as "FRPPO compounds"), that, inter alia, inhibit glutaminyl-peptide cyclotransferase-like (isoQC) enzyme and/or glutaminyl-peptide cyclotransferase (QC) enzyme (e.g., inhibit or reduce or block the activity or function of isoQC and/or QC enzyme). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit isoQC and/or QC enzyme; to treat disorders that are ameliorated by the inhibition of isoQC and/or QC enzyme; to treat cancer, atherosclerosis, fibrotic diseases, infectious diseases, Alzheimer's disease, etc.

Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

CHEMICAL COMPOUNDS

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also desc